Free Trial

Teva Pharmaceutical Industries (TEVA) Financials

Teva Pharmaceutical Industries logo
$17.72 +0.76 (+4.48%)
Closing price 05/27/2025 03:59 PM Eastern
Extended Trading
$18.02 +0.31 (+1.72%)
As of 04:31 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
Annual Income Statements for Teva Pharmaceutical Industries

Annual Income Statements for Teva Pharmaceutical Industries

This table shows Teva Pharmaceutical Industries' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019 12/31/2018 12/31/2017 12/31/2016 12/31/2015
Net Income / (Loss) Attributable to Common Shareholders
-1,639 -559 -2,446 417 -3,990 -999 -2,399 -16,525 68 1,573
Consolidated Net Income / (Loss)
-1,959 -615 -2,499 456 -4,099 -1,000 -2,472 -16,449 311 1,597
Net Income / (Loss) Continuing Operations
-1,959 -615 -2,499 456 -4,100 -1,000 -2,472 -16,449 311 1,597
Total Pre-Tax Income
-1,284 -624 -3,163 658 -4,406 -1,265 -2,596 -18,379 824 2,352
Total Operating Income
-303 433 -2,197 1,716 -3,572 -443 -1,637 -17,484 2,154 3,352
Total Gross Profit
8,064 7,645 6,973 7,594 7,726 7,537 8,296 10,615 11,653 11,356
Total Revenue
16,544 15,846 14,925 15,878 16,659 16,887 18,271 21,853 21,903 19,652
Operating Revenue
16,544 15,846 14,925 15,878 16,659 16,887 18,271 21,853 21,903 19,652
Total Cost of Revenue
8,481 8,200 7,952 8,284 8,933 9,351 9,975 11,237 10,250 8,296
Operating Cost of Revenue
8,481 8,200 7,952 8,284 8,933 9,351 9,975 11,237 10,250 8,296
Total Operating Expenses
8,366 7,213 9,170 5,879 11,297 7,980 9,933 28,099 9,499 8,004
Selling, General & Admin Expense
1,161 1,162 1,180 1,099 1,173 1,192 1,298 1,451 1,390 1,360
Marketing Expense
2,541 2,336 2,265 2,429 2,498 2,614 2,916 3,395 3,583 3,478
Research & Development Expense
998 953 838 967 997 1,010 1,213 1,778 2,077 1,525
Other Operating Expenses / (Income)
-14 -49 -107 -98 -40 -76 -291 -1,199 -769 -166
Impairment Charge
1,531 1,050 2,400 424 6,130 1,639 5,018 20,338 2,319 1,176
Restructuring Charge
1,388 718 512 341 479 423 987 1,836 - -
Other Special Charges / (Income)
761 1,043 2,082 717 60 1,178 -1,208 500 899 631
Total Other Income / (Expense), net
-981 -1,057 -966 -1,058 -834 -822 -959 -895 -1,330 -1,000
Other Income / (Expense), net
-981 -1,057 -966 -1,058 -834 -822 -959 -895 -1,330 -1,000
Income Tax Expense
676 -7.00 -643 211 -168 -278 -195 -1,933 521 634
Other Gains / (Losses), net
1.00 2.00 21 9.00 138 -13 -71 -3.00 8.00 -121
Net Income / (Loss) Attributable to Noncontrolling Interest
-320 -56 -53 39 -109 -2.00 -322 -184 -18 9.00
Basic Earnings per Share
($1.45) ($0.50) ($2.20) $0.38 ($3.64) ($0.91) ($2.35) ($16.26) $0.07 $1.84
Weighted Average Basic Shares Outstanding
1.13B 1.12B 1.11B 1.10B 1.10B 1.09B 1.02B 1.02B 955M 855M
Diluted Earnings per Share
($1.45) ($0.50) ($2.20) $0.38 ($3.64) ($0.91) ($2.35) ($16.26) $0.07 $1.82
Weighted Average Diluted Shares Outstanding
1.13B 1.12B 1.11B 1.11B 1.10B 1.09B 1.02B 1.02B 961M 1.02B
Weighted Average Basic & Diluted Shares Outstanding
1.13B 1.12B 1.11B 1.10B 1.10B 1.09B 1.02B 1.02B 1.12B 1.02B

Quarterly Income Statements for Teva Pharmaceutical Industries

This table shows Teva Pharmaceutical Industries' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 3/31/2025 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Net Income / (Loss) Attributable to Common Shareholders
214 -217 -437 -846 -139 464 69 -872 -220 -1,315 56
Consolidated Net Income / (Loss)
220 -276 -390 -874 -419 467 77 -906 -253 -1,346 58
Net Income / (Loss) Continuing Operations
220 -276 -390 -874 -419 467 77 -906 -253 -1,345 58
Total Pre-Tax Income
294 -247 -324 -246 -467 506 65 -923 -272 -1,198 166
Total Operating Income
519 -29 -51 -5.00 -218 755 345 -654 -13 -954 419
Total Gross Profit
1,877 2,121 2,148 2,024 1,771 2,416 1,851 1,796 1,582 1,770 1,669
Total Revenue
3,891 4,229 4,332 4,164 3,819 4,457 3,850 3,878 3,661 3,883 3,595
Operating Revenue
3,891 4,229 4,332 4,164 3,819 4,457 3,850 3,878 3,661 3,883 3,595
Total Cost of Revenue
2,014 2,110 2,183 2,140 2,048 2,040 1,999 2,082 2,079 2,113 1,926
Operating Cost of Revenue
2,014 2,110 2,183 2,140 2,048 2,040 1,999 2,082 2,079 2,113 1,926
Total Operating Expenses
1,356 2,150 2,198 2,030 1,988 1,662 1,506 2,450 1,595 2,722 1,250
Selling, General & Admin Expense
297 302 298 283 278 291 268 307 296 288 283
Marketing Expense
622 651 626 656 608 611 576 603 546 548 539
Research & Development Expense
247 247 240 269 242 226 253 240 234 210 175
Other Operating Expenses / (Income)
5.00 8.00 -21 -2.00 1.00 -5.00 -9.00 -33 -2.00 -19 -2.00
Impairment Charge
121 362 628 461 80 5.00 104 763 178 1,431 24
Restructuring Charge
-22 458 -23 280 673 - - 108 110 230 36
Other Special Charges / (Income)
86 122 450 83 106 34 314 462 233 34 195
Total Other Income / (Expense), net
-225 -218 -272 -241 -250 -249 -280 -268 -260 -245 -252
Other Income / (Expense), net
-225 -218 -272 -241 -250 -249 -280 -268 -260 -245 -252
Income Tax Expense
74 29 69 630 -52 40 -12 -16 -19 148 107
Other Gains / (Losses), net
0.00 - 3.00 2.00 -4.00 1.00 0.00 1.00 0.00 1.00 -1.00
Net Income / (Loss) Attributable to Noncontrolling Interest
6.00 -58 47 -29 -280 4.00 8.00 -35 -33 -32 3.00
Basic Earnings per Share
$0.19 ($0.19) ($0.39) ($0.75) ($0.12) $0.42 $0.06 ($0.78) ($0.20) ($1.18) $0.05
Weighted Average Basic Shares Outstanding
1.14B 1.13B 1.13B 1.13B 1.12B 1.12B 1.12B 1.12B 1.12B 1.11B 1.11B
Diluted Earnings per Share
$0.18 ($0.19) ($0.39) ($0.75) ($0.12) $0.42 $0.06 ($0.78) ($0.20) ($1.18) $0.05
Weighted Average Diluted Shares Outstanding
1.16B 1.13B 1.13B 1.13B 1.12B 1.12B 1.14B 1.12B 1.12B 1.11B 1.12B
Weighted Average Basic & Diluted Shares Outstanding
1.15B 1.13B 1.13B 1.13B 1.13B 1.12B 1.12B 1.12B 1.12B 1.11B 1.11B

Annual Cash Flow Statements for Teva Pharmaceutical Industries

This table details how cash moves in and out of Teva Pharmaceutical Industries' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019 12/31/2018 12/31/2017 12/31/2016 12/31/2015
Net Change in Cash & Equivalents
74 393 636 1,850 202 1,073 4,607 -25 -5,958 4,720
Net Cash From Operating Activities
1,247 1,368 1,590 798 1,216 748 2,446 2,225 3,890 5,542
Net Cash From Continuing Operating Activities
1,247 1,368 1,590 2,499 1,216 1,644 6,092 2,225 3,890 5,542
Net Income / (Loss) Continuing Operations
-1,959 -615 -2,499 456 -4,099 -1,000 -2,472 -16,449 311 1,597
Consolidated Net Income / (Loss)
-1,959 -615 -2,499 456 -4,099 -1,000 -2,472 -16,449 311 1,597
Depreciation Expense
1,059 1,153 1,308 1,330 1,557 1,722 1,842 2,112 1,524 1,308
Non-Cash Adjustments To Reconcile Net Income
2,656 1,158 2,581 1,391 6,542 2,273 3,960 20,525 2,170 1,287
Changes in Operating Assets and Liabilities, net
-509 -328 200 -678 -2,784 -1,351 -884 -3,963 -115 1,350
Net Cash From Investing Activities
792 968 656 1,523 863 1,355 1,866 3,446 -34,405 -5,565
Net Cash From Continuing Investing Activities
792 968 656 1,523 863 1,355 1,866 3,446 -34,405 -5,565
Purchase of Property, Plant & Equipment
-498 -526 -548 -562 -578 -525 -651 -874 -901 -772
Acquisitions
-15 0.00 -7.00 0.00 0.00 - - - -36,148 -3,309
Purchase of Investments
-71 -46 -1.00 -47 -55 -8.00 -119 -200 -481 -2,003
Divestitures
43 68 68 311 67 343 - 43 - -
Sale and/or Maturity of Investments
40 0.00 4.00 172 12 2.00 890 3,477 2,002 524
Other Investing Activities, net
1,293 1,472 1,140 1,649 1,417 1,543 1,746 1,000 1,123 -5.00
Net Cash From Financing Activities
-1,791 -1,913 -1,487 -2,172 -1,885 -1,926 -3,351 -5,750 25,217 4,805
Net Cash From Continuing Financing Activities
-1,791 -1,913 -1,487 -2,172 -1,885 -1,926 -3,351 -5,750 25,217 4,805
Repayment of Debt
-1,649 -5,064 -1,487 -2,381 -2,435 -2,374 -7,763 -5,057 -1,168 -2,699
Payment of Dividends
-78 0.00 0.00 - - -52 -22 -1,199 -1,558 -1,155
Issuance of Debt
0.00 3,151 0.00 700 550 500 4,434 506 27,250 2,128
Other Financing Activities, net
-64 0.00 0.00 -491 - 0.00 - - 35 388
Other Net Changes in Cash
-174 -30 -123 - 8.00 - - 54 -660 -
Cash Interest Paid
1,004 1,078 948 913 846 840 815 795 290 243
Cash Income Taxes Paid
471 298 543 495 709 552 420 106 341 802

Quarterly Cash Flow Statements for Teva Pharmaceutical Industries

This table details how cash moves in and out of Teva Pharmaceutical Industries' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 3/31/2025 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Net Change in Cash & Equivalents
-1,603 -18 1,061 -733 -236 977 -420 494 -658 576 167
Net Cash From Operating Activities
-105 575 693 103 -124 1,184 5.00 324 -145 973 543
Net Cash From Continuing Operating Activities
-105 575 693 103 -124 1,184 5.00 324 -145 973 543
Net Income / (Loss) Continuing Operations
220 -275 -390 -875 -419 467 77 -906 -253 -1,347 59
Consolidated Net Income / (Loss)
220 -275 -390 -875 -419 467 77 -906 -253 -1,347 59
Depreciation Expense
244 269 259 259 272 266 283 300 304 306 321
Non-Cash Adjustments To Reconcile Net Income
111 831 557 561 707 84 76 773 225 1,490 65
Changes in Operating Assets and Liabilities, net
-680 -250 267 158 -684 367 -431 157 -421 524 98
Net Cash From Investing Activities
201 202 268 178 144 301 184 302 181 168 147
Net Cash From Continuing Investing Activities
201 202 268 178 144 301 184 302 181 168 147
Purchase of Property, Plant & Equipment
-127 -129 -148 -97 -124 -119 -149 -119 -139 -142 -122
Acquisitions
0.00 - - - - - - - - - -
Purchase of Investments
-11 -15 -1.00 -43 -12 -2.00 -38 -2.00 -4.00 1.00 2.00
Divestitures
17 19 38 1.00 -15 - 10 56 2.00 23 2.00
Other Investing Activities, net
322 342 339 317 295 422 361 367 322 282 268
Net Cash From Financing Activities
-1,744 -674 - -966 -151 -576 -576 -55 -706 -711 -440
Net Cash From Continuing Financing Activities
-1,743 -674 - -966 -151 -576 -576 -55 -706 -711 -440
Repayment of Debt
-1,365 -674 - -966 -9.00 -576 -1,276 -55 -3,157 -711 -440
Payment of Dividends
-340 - - - -78 - - - 0.00 - -
Other Financing Activities, net
-38 - - - -64 - - - 0.00 - -
Other Net Changes in Cash
45 -121 100 -49 -104 68 -33 -77 12 146 -84

Annual Balance Sheets for Teva Pharmaceutical Industries

This table presents Teva Pharmaceutical Industries' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019 12/31/2018 12/31/2017 12/31/2016 12/31/2015
Total Assets
39,326 43,479 44,011 47,666 50,640 57,470 60,683 70,615 93,057 54,233
Total Current Assets
12,552 12,485 12,051 12,573 13,005 13,464 13,794 15,382 17,228 18,398
Cash & Equivalents
3,300 3,226 2,801 2,165 2,177 1,975 1,782 963 988 6,946
Accounts Receivable
3,059 3,408 3,696 4,529 4,581 5,676 5,822 7,128 7,523 5,350
Inventories, net
3,007 4,021 3,833 3,818 4,403 4,422 4,731 4,924 4,954 3,966
Prepaid Expenses
1,006 1,255 1,162 1,075 945 870 899 1,100 1,629 910
Other Current Assets
409 504 549 965 710 434 468 701 2,134 491
Other Current Nonoperating Assets
1,771 70 10 19 189 87 92 566 - -
Plant, Property, & Equipment, net
4,581 5,750 5,739 5,982 6,296 6,436 6,868 7,673 8,073 6,544
Total Noncurrent Assets
22,193 25,243 26,221 29,112 31,339 37,569 40,021 47,560 67,756 29,291
Goodwill
15,147 17,177 17,633 20,040 20,624 24,846 24,917 28,414 44,409 19,025
Intangible Assets
4,418 5,387 6,270 7,466 8,923 11,232 14,005 17,640 21,487 7,675
Noncurrent Deferred & Refundable Income Taxes
1,799 1,812 1,458 596 695 386 368 574 625 250
Other Noncurrent Operating Assets
829 867 860 1,010 1,097 1,105 731 932 1,235 2,341
Total Liabilities & Shareholders' Equity
39,326 43,479 44,011 47,666 50,640 57,470 60,683 70,615 93,057 54,233
Total Liabilities
33,606 35,353 35,413 36,422 39,579 42,407 44,889 51,870 58,064 24,306
Total Current Liabilities
12,796 12,247 11,469 11,027 13,164 13,674 14,322 17,921 18,488 13,005
Short-Term Debt
1,781 1,672 2,109 1,426 3,188 2,345 2,216 3,646 3,276 1,585
Accounts Payable
2,203 2,602 1,887 1,686 1,756 1,718 1,853 2,069 2,157 1,918
Accrued Expenses
2,792 2,771 2,151 2,208 1,780 1,869 1,868 3,014 3,405 1,681
Current Employee Benefit Liabilities
624 611 566 563 685 693 870 549 - -
Other Current Liabilities
4,698 4,579 4,755 5,144 5,757 7,048 7,515 8,605 9,534 7,821
Other Current Nonoperating Liabilities
698 13 - - - - - 38 116 0.00
Total Noncurrent Liabilities
20,809 23,106 23,944 25,395 26,414 28,733 30,567 33,949 39,576 11,301
Long-Term Debt
16,002 18,161 19,103 21,617 22,731 24,562 26,700 28,829 32,524 8,358
Noncurrent Deferred & Payable Income Tax Liabilities
483 606 548 784 964 1,096 2,140 3,277 5,413 1,748
Other Noncurrent Operating Liabilities
4,324 4,339 4,294 2,994 2,719 3,075 1,727 1,843 1,639 1,195
Commitments & Contingencies
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Redeemable Noncontrolling Interest
340 0.00 - - - - - - - -
Total Equity & Noncontrolling Interests
5,380 8,126 8,598 11,244 11,061 15,063 15,794 18,745 34,993 29,927
Total Preferred & Common Equity
5,373 7,506 7,804 10,278 10,026 13,972 14,707 17,359 33,337 29,769
Total Common Equity
5,373 7,505 7,804 10,278 10,027 13,972 14,707 13,728 29,717 26,478
Common Stock
27,822 27,864 27,745 27,618 27,500 27,368 27,266 23,533 23,463 17,809
Retained Earnings
-15,173 -13,534 -12,975 -10,529 -10,946 -6,956 -5,958 -3,803 13,607 14,851
Treasury Stock
-4,128 -4,128 -4,128 -4,128 -4,128 -4,128 -4,142 -4,149 -4,194 -4,227
Accumulated Other Comprehensive Income / (Loss)
-3,148 -2,697 -2,838 -2,683 -2,399 -2,312 -2,459 -1,853 -3,159 -1,955
Noncontrolling Interest
7.00 620 794 966 1,035 1,091 1,087 1,386 1,656 158

Quarterly Balance Sheets for Teva Pharmaceutical Industries

This table presents Teva Pharmaceutical Industries' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q1 2025 Q3 2024 Q2 2024 Q1 2024 Q3 2023 Q2 2023 Q1 2023 Q3 2022
Period end date 3/31/2025 9/30/2024 6/30/2024 3/31/2024 9/30/2023 6/30/2023 3/31/2023 9/30/2022
Total Assets
38,415 41,758 41,338 42,773 42,088 43,095 43,456 44,252
Total Current Assets
11,528 12,314 11,632 12,297 11,425 12,088 11,501 11,453
Cash & Equivalents
1,697 3,319 2,258 2,991 2,249 2,669 2,143 2,225
Accounts Receivable
3,384 3,462 3,766 3,456 3,385 3,539 3,435 3,730
Inventories, net
3,247 3,959 3,927 3,949 4,051 4,109 4,118 3,859
Prepaid Expenses
1,018 1,127 1,096 1,336 1,168 1,228 1,253 1,045
Other Current Assets
368 445 517 495 520 486 542 579
Other Current Nonoperating Assets
1,814 2.00 69 70 51 56 10 16
Plant, Property, & Equipment, net
4,631 5,672 5,573 5,618 5,622 5,712 5,751 5,568
Total Noncurrent Assets
22,255 23,773 24,133 24,857 25,041 25,295 26,205 27,232
Goodwill
15,477 16,124 16,488 17,007 16,885 17,118 17,799 18,433
Intangible Assets
4,189 4,756 4,853 5,056 5,525 5,738 5,964 6,393
Noncurrent Deferred & Refundable Income Taxes
1,762 2,070 2,000 1,960 1,748 1,578 1,572 1,546
Other Noncurrent Operating Assets
827 823 792 834 883 861 870 860
Total Liabilities & Shareholders' Equity
38,415 41,758 41,338 42,773 42,088 43,095 43,456 44,252
Total Liabilities
32,146 35,375 34,774 35,230 34,576 35,387 34,844 34,734
Total Current Liabilities
11,157 13,797 13,037 13,792 11,394 11,843 10,411 11,534
Short-Term Debt
421 2,580 2,094 3,060 1,479 1,980 1,023 2,769
Accounts Payable
2,290 2,371 2,366 2,439 2,280 2,508 2,381 1,635
Accrued Expenses
2,952 2,984 2,840 2,784 2,741 2,498 2,267 2,041
Current Employee Benefit Liabilities
474 619 492 492 530 451 432 496
Other Current Liabilities
4,660 5,026 4,891 4,755 4,362 4,406 4,309 4,593
Other Current Nonoperating Liabilities
358 216 356 262 - - - -
Total Noncurrent Liabilities
20,990 21,578 21,737 21,438 23,182 23,543 24,433 23,200
Long-Term Debt
16,230 16,400 16,547 16,584 18,495 18,698 19,668 18,497
Noncurrent Deferred & Payable Income Tax Liabilities
461 538 553 569 544 534 550 503
Other Noncurrent Operating Liabilities
4,299 4,639 4,637 4,285 4,142 4,311 4,214 4,200
Commitments & Contingencies
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Redeemable Noncontrolling Interest
0.00 - - - - - - -
Total Equity & Noncontrolling Interests
6,269 6,383 6,563 7,543 7,512 7,708 8,612 9,519
Total Preferred & Common Equity
6,262 6,065 6,359 7,278 6,929 7,052 7,860 8,767
Total Common Equity
6,262 6,065 6,359 7,278 6,929 7,050 7,861 8,768
Common Stock
28,023 27,918 27,887 27,854 27,837 27,805 27,776 27,709
Retained Earnings
-14,958 -14,956 -14,519 -13,673 -13,870 -13,950 -13,086 -11,660
Treasury Stock
-4,128 -4,128 -4,128 -4,128 -4,128 -4,128 -4,128 -4,128
Accumulated Other Comprehensive Income / (Loss)
-2,675 -2,769 -2,881 -2,775 -2,910 -2,677 -2,701 -3,153
Noncontrolling Interest
7.00 319 204 265 582 656 751 751

Annual Metrics And Ratios for Teva Pharmaceutical Industries

This table displays calculated financial ratios and metrics derived from Teva Pharmaceutical Industries' official financial filings.

Metric 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019 12/31/2018 12/31/2017 12/31/2016 12/31/2015
Growth Metrics
- - - - - - - - - -
Revenue Growth
4.40% 6.17% -6.00% -4.69% -1.35% -7.57% -16.39% -0.23% 11.45% -3.06%
EBITDA Growth
-142.53% 128.52% -193.31% 169.78% -723.41% 160.61% 95.36% -792.80% -35.85% -28.88%
EBIT Growth
-105.77% 80.27% -580.70% 114.93% -248.30% 51.27% 85.88% -2,330.46% -64.97% -35.35%
NOPAT Growth
-169.98% 119.71% -231.93% 146.62% -706.32% 72.94% 90.64% -1,645.18% -67.65% -26.01%
Net Income Growth
-218.54% 75.39% -648.03% 111.12% -309.90% 59.55% 84.97% -5,389.07% -80.53% -47.50%
EPS Growth
-190.00% 77.27% -678.95% 110.44% -300.00% 61.28% 85.55% -23,328.57% -96.15% -48.88%
Operating Cash Flow Growth
-8.85% -13.96% 99.25% -34.38% 62.57% -69.42% 9.93% -42.80% -29.81% 8.09%
Free Cash Flow Firm Growth
102.73% -26.25% -3.04% 31.57% 6.75% -54.45% -27.74% 121.97% -3,792.71% -82.62%
Invested Capital Growth
-22.46% -8.62% -15.90% -7.25% -13.27% -6.84% -13.86% -28.88% 112.37% 4.67%
Revenue Q/Q Growth
-1.36% 3.76% -1.43% -2.19% -0.08% 3.00% -4.64% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth
-142.86% 146.57% -126.77% -16.26% 5.10% 115.62% 92.77% 0.00% 0.00% 0.00%
EBIT Q/Q Growth
-141.81% 73.21% -47.80% -32.09% 3.80% 72.58% 79.09% 0.00% 0.00% 0.00%
NOPAT Q/Q Growth
-162.99% 133.93% -88.42% -26.71% 6.71% 88.20% 85.75% 0.00% 0.00% 0.00%
Net Income Q/Q Growth
-61.10% 74.67% -91.49% -40.70% 2.06% 76.84% 77.44% 0.00% 0.00% 0.00%
EPS Q/Q Growth
-72.62% 76.19% -89.66% -42.42% 0.82% 76.61% 78.42% 0.00% 0.00% 0.00%
Operating Cash Flow Q/Q Growth
-32.81% 18.24% 48.18% 18.57% -14.55% 29.64% -16.75% 0.00% 0.00% 0.00%
Free Cash Flow Firm Q/Q Growth
63.31% 6.71% -5.38% 34.51% -23.56% -23.69% 0.00% 0.00% 0.00% 0.00%
Invested Capital Q/Q Growth
-14.06% -2.04% -5.42% -3.10% 1.00% -1.72% -8.21% 0.00% 0.00% 0.00%
Profitability Metrics
- - - - - - - - - -
Gross Margin
48.74% 48.25% 46.72% 47.83% 46.38% 44.63% 45.41% 48.57% 53.20% 57.79%
EBITDA Margin
-1.36% 3.34% -12.43% 12.52% -17.10% 2.71% -4.13% -74.44% 10.72% 18.62%
Operating Margin
-1.83% 2.73% -14.72% 10.81% -21.44% -2.62% -8.96% -80.01% 9.83% 17.06%
EBIT Margin
-7.76% -3.94% -21.19% 4.14% -26.45% -7.49% -14.21% -84.10% 3.76% 11.97%
Profit (Net Income) Margin
-11.84% -3.88% -16.74% 2.87% -24.61% -5.92% -13.53% -75.27% 1.42% 8.13%
Tax Burden Percent
152.57% 98.56% 79.01% 69.30% 93.03% 79.05% 95.22% 89.50% 37.74% 67.90%
Interest Burden Percent
100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Effective Tax Rate
0.00% 0.00% 0.00% 32.07% 0.00% 0.00% 0.00% 0.00% 63.23% 26.96%
Return on Invested Capital (ROIC)
-0.97% 1.17% -5.20% 3.49% -6.71% -0.75% -2.48% -20.46% 1.54% 7.61%
ROIC Less NNEP Spread (ROIC-NNEP)
-12.63% -4.08% -10.10% 0.30% -13.32% -3.41% -7.05% -33.23% -1.00% -7.74%
Return on Net Nonoperating Assets (RNNOA)
-27.33% -8.53% -19.98% 0.59% -24.67% -5.73% -11.84% -40.76% -0.58% -1.61%
Return on Equity (ROE)
-28.30% -7.35% -25.19% 4.09% -31.38% -6.48% -14.31% -61.22% 0.96% 5.99%
Cash Return on Invested Capital (CROIC)
24.34% 10.18% 12.06% 11.02% 7.50% 6.33% 12.42% 13.29% -70.41% 3.05%
Operating Return on Assets (OROA)
-3.10% -1.43% -6.90% 1.34% -8.15% -2.14% -3.95% -22.46% 1.12% 4.67%
Return on Assets (ROA)
-4.73% -1.41% -5.45% 0.93% -7.58% -1.69% -3.77% -20.10% 0.42% 3.17%
Return on Common Equity (ROCE)
-26.32% -6.73% -22.95% 3.72% -28.83% -6.02% -11.78% -49.49% 0.83% 5.60%
Return on Equity Simple (ROE_SIMPLE)
-36.46% -8.19% -32.02% 4.44% -40.88% -7.16% -16.81% -94.76% 0.93% 5.36%
Net Operating Profit after Tax (NOPAT)
-212 303 -1,538 1,166 -2,500 -310 -1,146 -12,239 792 2,448
NOPAT Margin
-1.28% 1.91% -10.30% 7.34% -15.01% -1.84% -6.27% -56.01% 3.62% 12.46%
Net Nonoperating Expense Percent (NNEP)
11.66% 5.25% 4.90% 3.20% 6.61% 2.66% 4.57% 12.78% 2.54% 15.34%
Return On Investment Capital (ROIC_SIMPLE)
-0.92% 1.08% -5.16% - - - - - - -
Cost of Revenue to Revenue
51.26% 51.75% 53.28% 52.17% 53.62% 55.37% 54.59% 51.42% 46.80% 42.21%
SG&A Expenses to Revenue
7.02% 7.33% 7.91% 6.92% 7.04% 7.06% 7.10% 6.64% 6.35% 6.92%
R&D to Revenue
6.03% 6.01% 5.61% 6.09% 5.98% 5.98% 6.64% 8.14% 9.48% 7.76%
Operating Expenses to Revenue
50.57% 45.52% 61.44% 37.03% 67.81% 47.26% 54.36% 128.58% 43.37% 40.73%
Earnings before Interest and Taxes (EBIT)
-1,284 -624 -3,163 658 -4,406 -1,265 -2,596 -18,379 824 2,352
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
-225 529 -1,855 1,988 -2,849 457 -754 -16,267 2,348 3,660
Valuation Ratios
- - - - - - - - - -
Price to Book Value (P/BV)
4.65 1.56 1.30 0.86 1.05 0.77 1.07 1.55 1.20 2.23
Price to Tangible Book Value (P/TBV)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Revenue (P/Rev)
1.51 0.74 0.68 0.56 0.63 0.63 0.86 0.97 1.63 3.00
Price to Earnings (P/E)
0.00 0.00 0.00 21.19 0.00 0.00 0.00 0.00 523.92 37.54
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 4.49% 3.88% 2.21%
Earnings Yield
0.00% 0.00% 0.00% 4.72% 0.00% 0.00% 0.00% 0.00% 0.19% 2.66%
Enterprise Value to Invested Capital (EV/IC)
2.08 1.17 1.09 0.96 1.02 0.92 1.03 1.16 1.08 1.99
Enterprise Value to Revenue (EV/Rev)
2.41 1.83 1.97 1.93 2.12 2.17 2.40 2.65 3.46 3.33
Enterprise Value to EBITDA (EV/EBITDA)
0.00 54.69 0.00 15.43 0.00 80.36 0.00 0.00 32.25 17.89
Enterprise Value to EBIT (EV/EBIT)
0.00 0.00 0.00 46.62 0.00 0.00 0.00 0.00 91.89 27.85
Enterprise Value to NOPAT (EV/NOPAT)
0.00 95.45 0.00 26.32 0.00 0.00 0.00 0.00 95.59 26.75
Enterprise Value to Operating Cash Flow (EV/OCF)
31.92 21.15 18.45 38.45 29.07 49.10 17.96 25.98 19.46 11.82
Enterprise Value to Free Cash Flow (EV/FCFF)
7.47 11.00 8.23 8.34 12.65 14.03 7.64 7.27 0.00 66.80
Leverage & Solvency
- - - - - - - - - -
Debt to Equity
3.11 2.44 2.47 2.05 2.34 1.79 1.83 1.73 1.02 0.33
Long-Term Debt to Equity
2.80 2.23 2.22 1.92 2.06 1.63 1.69 1.54 0.93 0.28
Financial Leverage
2.16 2.09 1.98 1.99 1.85 1.68 1.68 1.23 0.58 0.21
Leverage Ratio
5.98 5.23 4.62 4.41 4.14 3.83 3.80 3.05 2.27 1.89
Compound Leverage Factor
5.98 5.23 4.62 4.41 4.14 3.83 3.80 3.05 2.27 1.89
Debt to Total Capital
75.66% 70.94% 71.16% 67.21% 70.09% 64.11% 64.67% 63.40% 50.57% 24.94%
Short-Term Debt to Total Capital
7.58% 5.98% 7.07% 4.16% 8.62% 5.59% 4.96% 7.12% 4.63% 3.98%
Long-Term Debt to Total Capital
68.08% 64.96% 64.08% 63.05% 61.47% 58.52% 59.72% 56.28% 45.94% 20.96%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 7.09% 5.11% 8.25%
Noncontrolling Interests to Total Capital
1.48% 2.22% 2.66% 2.82% 2.80% 2.60% 2.43% 2.71% 2.34% 0.40%
Common Equity to Total Capital
22.86% 26.84% 26.18% 29.98% 27.11% 33.29% 32.89% 26.80% 41.98% 66.41%
Debt to EBITDA
-79.04 37.49 -11.44 11.59 -9.10 58.88 -38.35 -2.00 15.25 2.72
Net Debt to EBITDA
-64.37 31.39 -9.93 10.50 -8.33 54.56 -35.99 -1.94 14.83 0.82
Long-Term Debt to EBITDA
-71.12 34.33 -10.30 10.87 -7.98 53.75 -35.41 -1.77 13.85 2.28
Debt to NOPAT
-83.84 65.43 -13.79 19.77 -10.37 -86.77 -25.23 -2.65 45.20 4.06
Net Debt to NOPAT
-68.28 54.79 -11.97 17.91 -9.50 -80.40 -23.68 -2.57 43.95 1.22
Long-Term Debt to NOPAT
-75.45 59.92 -12.42 18.54 -9.09 -79.21 -23.30 -2.36 41.06 3.41
Altman Z-Score
0.21 0.09 -0.12 0.25 -0.10 0.20 0.22 -0.42 0.82 2.47
Noncontrolling Interest Sharing Ratio
6.99% 8.46% 8.87% 8.97% 8.13% 7.06% 17.67% 19.15% 13.44% 6.55%
Liquidity Ratios
- - - - - - - - - -
Current Ratio
0.98 1.02 1.05 1.14 0.99 0.98 0.96 0.86 0.93 1.41
Quick Ratio
0.50 0.54 0.57 0.61 0.51 0.56 0.53 0.45 0.46 0.95
Cash Flow Metrics
- - - - - - - - - -
Free Cash Flow to Firm (FCFF)
5,330 2,629 3,565 3,677 2,795 2,618 5,747 7,953 -36,205 980
Operating Cash Flow to CapEx
250.40% 260.08% 290.15% 141.99% 210.38% 142.48% 375.73% 254.58% 431.74% 717.88%
Free Cash Flow to Firm to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios
- - - - - - - - - -
Asset Turnover
0.40 0.36 0.33 0.32 0.31 0.29 0.28 0.27 0.30 0.39
Accounts Receivable Turnover
5.12 4.46 3.63 3.49 3.25 2.94 2.82 2.98 3.40 3.65
Inventory Turnover
2.41 2.09 2.08 2.02 2.02 2.04 2.07 2.28 2.30 1.99
Fixed Asset Turnover
3.20 2.76 2.55 2.59 2.62 2.54 2.51 2.78 3.00 3.01
Accounts Payable Turnover
3.53 3.65 4.45 4.81 5.14 5.24 5.09 5.32 5.03 3.26
Days Sales Outstanding (DSO)
71.34 81.82 100.57 104.71 112.37 124.26 129.35 122.35 107.26 99.91
Days Inventory Outstanding (DIO)
151.23 174.80 175.59 181.11 180.29 178.64 176.65 160.43 158.82 183.40
Days Payable Outstanding (DPO)
103.40 99.91 82.00 75.83 70.97 69.69 71.76 68.63 72.55 111.95
Cash Conversion Cycle (CCC)
119.17 156.71 194.16 209.99 221.69 233.20 234.24 214.15 193.52 171.36
Capital & Investment Metrics
- - - - - - - - - -
Invested Capital
19,131 24,673 26,999 32,102 34,613 39,908 42,836 49,729 69,921 32,924
Invested Capital Turnover
0.76 0.61 0.51 0.48 0.45 0.41 0.39 0.37 0.43 0.61
Increase / (Decrease) in Invested Capital
-5,542 -2,326 -5,103 -2,511 -5,295 -2,928 -6,893 -20,192 36,997 1,468
Enterprise Value (EV)
39,802 28,930 29,334 30,679 35,353 36,725 43,930 57,801 75,714 65,494
Market Capitalization
24,972 11,703 10,129 8,835 10,576 10,702 15,709 21,272 35,626 59,048
Book Value per Share
$4.74 $6.70 $7.03 $9.32 $9.15 $12.79 $14.44 $12.23 $29.25 $27.68
Tangible Book Value per Share
($12.53) ($13.43) ($14.50) ($15.62) ($17.81) ($20.24) ($23.77) ($28.80) ($35.61) ($0.23)
Total Capital
23,503 27,959 29,810 34,287 36,980 41,970 44,710 51,220 70,793 39,870
Total Debt
17,783 19,833 21,212 23,043 25,919 26,907 28,916 32,475 35,800 9,943
Total Long-Term Debt
16,002 18,161 19,103 21,617 22,731 24,562 26,700 28,829 32,524 8,358
Net Debt
14,483 16,607 18,411 20,878 23,742 24,932 27,134 31,512 34,812 2,997
Capital Expenditures (CapEx)
498 526 548 562 578 525 651 874 901 772
Debt-free, Cash-free Net Working Capital (DFCFNWC)
-1,763 -1,316 -110 807 852 160 -94 144 1,028 32
Debt-free Net Working Capital (DFNWC)
1,537 1,910 2,691 2,972 3,029 2,135 1,688 1,107 2,016 6,978
Net Working Capital (NWC)
-244 238 582 1,546 -159 -210 -528 -2,539 -1,260 5,393
Net Nonoperating Expense (NNE)
1,747 918 961 710 1,599 690 1,326 4,210 481 851
Net Nonoperating Obligations (NNO)
13,411 16,547 18,401 20,858 23,552 24,845 27,042 30,984 34,928 2,997
Total Depreciation and Amortization (D&A)
1,059 1,153 1,308 1,330 1,557 1,722 1,842 2,112 1,524 1,308
Debt-free, Cash-free Net Working Capital to Revenue
-10.66% -8.30% -0.74% 5.08% 5.11% 0.95% -0.51% 0.66% 4.69% 0.16%
Debt-free Net Working Capital to Revenue
9.29% 12.05% 18.03% 18.72% 18.18% 12.64% 9.24% 5.07% 9.20% 35.51%
Net Working Capital to Revenue
-1.47% 1.50% 3.90% 9.74% -0.95% -1.24% -2.89% -11.62% -5.75% 27.44%
Earnings Adjustments
- - - - - - - - - -
Adjusted Basic Earnings per Share
($1.45) ($0.50) ($2.12) $0.38 ($3.64) ($0.91) ($2.35) ($16.26) $0.00 $1.84
Adjusted Weighted Average Basic Shares Outstanding
1.13B 1.12B 1.11B 1.10B 1.10B 1.09B 1.02B 1.02B 0.00 855M
Adjusted Diluted Earnings per Share
($1.45) ($0.50) ($2.12) $0.38 ($3.64) ($0.91) ($2.35) ($16.26) $0.00 $1.82
Adjusted Weighted Average Diluted Shares Outstanding
1.13B 1.12B 1.11B 1.11B 1.10B 1.09B 1.02B 1.12B 0.00 1.02B
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
1.13B 1.12B 1.11B 1.10B 1.10B 1.09B 1.09B 1.12B 0.00 1.02B
Normalized Net Operating Profit after Tax (NOPAT)
2,364 2,271 1,958 2,173 2,168 1,958 2,212 3,633 3,760 3,768
Normalized NOPAT Margin
14.29% 14.33% 13.12% 13.68% 13.01% 11.59% 12.11% 16.62% 17.17% 19.18%
Pre Tax Income Margin
-7.76% -3.94% -21.19% 4.14% -26.45% -7.49% -14.21% -84.10% 3.76% 11.97%
Debt Service Ratios
- - - - - - - - - -
EBIT to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios
- - - - - - - - - -
Dividend Payout Ratio
-3.98% 0.00% 0.00% 0.00% 0.00% -5.20% -0.89% -7.29% 500.96% 72.32%
Augmented Payout Ratio
-3.98% 0.00% 0.00% 0.00% 0.00% -5.20% -0.89% -7.29% 500.96% 99.81%

Quarterly Metrics And Ratios for Teva Pharmaceutical Industries

This table displays calculated financial ratios and metrics derived from Teva Pharmaceutical Industries' official financial filings.

Metric Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 3/31/2025 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Growth Metrics
- - - - - - - - - - -
Revenue Growth
1.89% -5.12% 12.52% 7.37% 4.32% 14.78% 7.09% 2.43% 0.00% -5.27% -7.51%
EBITDA Growth
374.49% -97.15% -118.39% 102.09% -732.26% 186.45% -28.69% 22.44% 104.78% -720.14% -31.36%
EBIT Growth
162.82% -148.81% -596.92% 73.32% -71.43% 142.20% -61.08% 20.52% 71.88% -581.25% -56.28%
NOPAT Growth
354.50% -102.92% -108.74% 99.24% -1,576.92% 204.12% 174.43% 31.09% 98.18% -1,338.96% -70.16%
Net Income Growth
152.51% -159.10% -606.49% 3.53% -65.61% 134.70% 32.76% -249.81% 73.42% -785.53% -80.79%
EPS Growth
250.00% -145.24% -750.00% 3.85% 40.00% 135.59% 20.00% -271.43% 76.74% -742.86% -80.77%
Operating Cash Flow Growth
15.32% -51.44% 13,760.00% -68.21% 14.48% 21.69% -99.08% 163.41% -195.92% 113.38% 2.65%
Free Cash Flow Firm Growth
91.79% 82.76% -23.22% -34.78% -31.76% -31.88% -20.44% 6.86% 44.69% 72.92% 188.23%
Invested Capital Growth
-18.94% -22.46% -11.62% -9.46% -10.18% -8.62% -11.76% -13.99% -12.38% -15.90% -13.84%
Revenue Q/Q Growth
-7.99% -2.38% 4.03% 9.03% -14.31% 15.77% -0.72% 5.93% -5.72% 8.01% -5.04%
EBITDA Q/Q Growth
2,345.45% 134.38% -592.31% 106.63% -126.52% 121.84% 155.95% -2,106.45% 103.47% -282.99% 160.85%
EBIT Q/Q Growth
219.03% 23.53% -31.30% 47.44% -198.94% 678.46% 107.05% -237.73% 77.23% -817.96% 114.40%
NOPAT Q/Q Growth
2,013.14% 43.14% -920.00% 97.71% -123.09% 70.13% 189.27% -4,930.77% 98.64% -548.42% 122.42%
Net Income Q/Q Growth
179.71% 29.23% 55.38% -108.59% -196.77% 506.49% 108.50% -258.10% 81.20% -2,420.69% 122.39%
EPS Q/Q Growth
194.74% 51.28% 48.00% -525.00% -131.58% 600.00% 107.69% -290.00% 83.05% -2,460.00% 123.81%
Operating Cash Flow Q/Q Growth
-118.26% -17.03% 572.82% 183.06% -110.47% 23,580.00% -98.46% 323.45% -114.90% 79.19% 341.46%
Free Cash Flow Firm Q/Q Growth
-9.30% 90.98% 19.25% -7.16% -12.92% -19.77% 1.30% -2.87% -13.72% -6.29% 36.05%
Invested Capital Q/Q Growth
3.32% -14.06% -4.18% -4.73% -1.11% -2.04% -1.84% -5.49% 0.56% -5.42% -4.33%
Profitability Metrics
- - - - - - - - - - -
Gross Margin
48.24% 50.15% 49.58% 48.61% 46.37% 54.21% 48.08% 46.31% 43.21% 45.58% 46.43%
EBITDA Margin
13.83% 0.52% -1.48% 0.31% -5.13% 17.32% 9.04% -16.04% 0.85% -23.00% 13.57%
Operating Margin
13.34% -0.69% -1.18% -0.12% -5.71% 16.94% 8.96% -16.86% -0.36% -24.57% 11.66%
EBIT Margin
7.56% -5.84% -7.46% -5.91% -12.25% 11.35% 1.69% -23.78% -7.46% -30.88% 4.65%
Profit (Net Income) Margin
5.65% -6.53% -9.00% -20.99% -10.97% 10.48% 2.00% -23.36% -6.91% -34.66% 1.61%
Tax Burden Percent
74.83% 111.74% 120.37% 355.28% 89.72% 92.29% 118.46% 98.16% 93.01% 112.35% 34.94%
Interest Burden Percent
100.00% 100.00% 100.31% 100.00% 99.79% 100.00% 100.00% 100.11% 99.63% 99.92% 99.40%
Effective Tax Rate
25.17% 0.00% 0.00% 0.00% 0.00% 7.91% -18.46% 0.00% 0.00% 0.00% 64.46%
Return on Invested Capital (ROIC)
7.51% -0.36% -0.58% -0.06% -2.48% 9.57% 6.03% -6.39% -0.13% -8.69% 2.03%
ROIC Less NNEP Spread (ROIC-NNEP)
6.40% -2.07% -2.69% -5.08% -3.99% 8.26% 4.23% -8.75% -1.37% -12.14% 1.59%
Return on Net Nonoperating Assets (RNNOA)
14.06% -4.48% -6.51% -12.34% -8.73% 17.26% 9.11% -18.94% -2.85% -24.02% 3.08%
Return on Equity (ROE)
21.58% -4.84% -7.09% -12.39% -11.22% 26.83% 15.14% -25.33% -2.98% -32.71% 5.11%
Cash Return on Invested Capital (CROIC)
22.30% 24.34% 13.76% 12.44% 11.35% 10.18% 9.17% 12.01% 9.59% 12.06% 12.22%
Operating Return on Assets (OROA)
3.09% -2.33% -2.98% -2.28% -4.55% 4.11% 0.60% -8.02% -2.46% -10.05% 1.53%
Return on Assets (ROA)
2.31% -2.61% -3.60% -8.10% -4.07% 3.80% 0.71% -7.88% -2.28% -11.29% 0.53%
Return on Common Equity (ROCE)
21.15% -4.50% -6.63% -11.64% -10.51% 24.56% 13.96% -23.24% -2.72% -29.81% 4.69%
Return on Equity Simple (ROE_SIMPLE)
-21.08% 0.00% -20.05% -11.78% -10.73% 0.00% -35.04% -34.70% -22.90% 0.00% -14.89%
Net Operating Profit after Tax (NOPAT)
388 -20 -36 -3.50 -153 695 409 -458 -9.10 -668 149
NOPAT Margin
9.98% -0.48% -0.82% -0.08% -4.00% 15.60% 10.62% -11.81% -0.25% -17.20% 4.14%
Net Nonoperating Expense Percent (NNEP)
1.11% 1.71% 2.11% 5.03% 1.51% 1.31% 1.81% 2.36% 1.24% 3.46% 0.45%
Return On Investment Capital (ROIC_SIMPLE)
1.69% -0.09% - - - 2.49% - - - -2.24% -
Cost of Revenue to Revenue
51.76% 49.89% 50.39% 51.39% 53.63% 45.77% 51.92% 53.69% 56.79% 54.42% 53.57%
SG&A Expenses to Revenue
7.63% 7.14% 6.88% 6.80% 7.28% 6.53% 6.96% 7.92% 8.09% 7.42% 7.87%
R&D to Revenue
6.35% 5.84% 5.54% 6.46% 6.34% 5.07% 6.57% 6.19% 6.39% 5.41% 4.87%
Operating Expenses to Revenue
34.85% 50.84% 50.74% 48.75% 52.06% 37.29% 39.12% 63.18% 43.57% 70.10% 34.77%
Earnings before Interest and Taxes (EBIT)
294 -247 -323 -246 -468 506 65 -922 -273 -1,199 167
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
538 22 -64 13 -196 772 348 -622 31 -893 488
Valuation Ratios
- - - - - - - - - - -
Price to Book Value (P/BV)
2.78 4.65 3.37 2.89 2.17 1.56 1.65 1.20 1.25 1.30 1.02
Price to Tangible Book Value (P/TBV)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Revenue (P/Rev)
1.05 1.51 1.22 1.13 0.99 0.74 0.75 0.56 0.66 0.68 0.59
Price to Earnings (P/E)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)
1.64 2.08 1.63 1.51 1.34 1.17 1.18 1.06 1.07 1.09 1.01
Enterprise Value to Revenue (EV/Rev)
1.95 2.41 2.17 2.15 2.05 1.83 1.95 1.80 1.95 1.97 1.90
Enterprise Value to EBITDA (EV/EBITDA)
63.63 0.00 69.32 37.35 108.39 54.69 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)
106.61 0.00 108.09 57.00 205.11 95.45 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)
25.58 31.92 19.61 29.96 23.57 21.15 25.70 15.99 19.50 18.45 26.80
Enterprise Value to Free Cash Flow (EV/FCFF)
6.58 7.47 11.15 11.50 11.20 11.00 12.07 8.13 10.45 8.23 7.63
Leverage & Solvency
- - - - - - - - - - -
Debt to Equity
2.66 3.11 2.97 2.84 2.60 2.44 2.66 2.68 2.40 2.47 2.23
Long-Term Debt to Equity
2.59 2.80 2.57 2.52 2.20 2.23 2.46 2.43 2.28 2.22 1.94
Financial Leverage
2.20 2.16 2.41 2.43 2.19 2.09 2.16 2.16 2.08 1.98 1.94
Leverage Ratio
5.88 5.98 6.03 5.92 5.34 5.23 5.07 5.08 4.80 4.62 4.39
Compound Leverage Factor
5.88 5.98 6.05 5.92 5.33 5.23 5.07 5.08 4.78 4.62 4.37
Debt to Total Capital
72.65% 75.66% 74.83% 73.96% 72.26% 70.94% 72.67% 72.85% 70.61% 71.16% 69.08%
Short-Term Debt to Total Capital
1.84% 7.58% 10.17% 8.31% 11.26% 5.98% 5.38% 6.98% 3.49% 7.07% 8.99%
Long-Term Debt to Total Capital
70.81% 68.08% 64.66% 65.65% 61.00% 64.96% 67.29% 65.87% 67.12% 64.08% 60.08%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.03% 1.48% 1.26% 0.81% 0.97% 2.22% 2.12% 2.31% 2.56% 2.66% 2.44%
Common Equity to Total Capital
27.32% 22.86% 23.91% 25.23% 26.77% 26.84% 25.21% 24.84% 26.83% 26.18% 28.48%
Debt to EBITDA
32.71 -79.04 36.15 19.89 65.05 37.49 -17.58 -20.76 -17.59 -11.44 -26.00
Net Debt to EBITDA
29.38 -64.37 29.83 17.48 55.14 31.39 -15.60 -18.08 -15.77 -9.93 -23.28
Long-Term Debt to EBITDA
31.89 -71.12 31.24 17.66 54.91 34.33 -16.28 -18.77 -16.72 -10.30 -22.61
Debt to NOPAT
54.81 -83.84 56.37 30.36 123.08 65.43 -22.36 -24.58 -19.75 -13.79 -26.05
Net Debt to NOPAT
49.22 -68.28 46.51 26.69 104.34 54.79 -19.84 -21.40 -17.70 -11.97 -23.33
Long-Term Debt to NOPAT
53.42 -75.45 48.71 26.95 103.91 59.92 -20.71 -22.22 -18.77 -12.42 -22.66
Altman Z-Score
0.25 0.30 0.18 0.16 0.12 0.17 0.11 -0.03 0.10 0.02 0.14
Noncontrolling Interest Sharing Ratio
1.97% 6.99% 6.48% 6.04% 6.29% 8.46% 7.83% 8.26% 8.83% 8.87% 8.27%
Liquidity Ratios
- - - - - - - - - - -
Current Ratio
1.03 0.98 0.89 0.89 0.89 1.02 1.00 1.02 1.10 1.05 0.99
Quick Ratio
0.46 0.50 0.49 0.46 0.47 0.54 0.49 0.52 0.54 0.57 0.52
Cash Flow Metrics
- - - - - - - - - - -
Free Cash Flow to Firm (FCFF)
5,008 5,522 2,891 2,425 2,611 3,021 3,766 3,717 3,827 4,435 4,733
Operating Cash Flow to CapEx
-82.68% 445.74% 468.24% 106.19% -100.00% 994.96% 3.36% 272.27% -104.32% 685.21% 445.08%
Free Cash Flow to Firm to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios
- - - - - - - - - - -
Asset Turnover
0.41 0.40 0.40 0.39 0.37 0.36 0.35 0.34 0.33 0.33 0.33
Accounts Receivable Turnover
4.86 5.12 4.90 4.46 4.64 4.46 4.29 3.75 3.88 3.63 3.89
Inventory Turnover
2.35 2.41 2.10 2.05 2.03 2.09 2.09 2.01 2.00 2.08 1.97
Fixed Asset Turnover
3.24 3.20 2.97 2.89 2.82 2.76 2.73 2.62 2.56 2.55 2.61
Accounts Payable Turnover
3.57 3.53 3.62 3.38 3.39 3.65 4.23 3.72 3.93 4.45 5.01
Days Sales Outstanding (DSO)
75.13 71.34 74.50 81.84 78.58 81.82 85.02 97.34 94.01 100.57 93.73
Days Inventory Outstanding (DIO)
155.47 151.23 173.80 178.26 180.22 174.80 174.49 181.57 182.95 175.59 185.67
Days Payable Outstanding (DPO)
102.17 103.40 100.92 108.12 107.68 99.91 86.36 98.13 92.96 82.00 72.85
Cash Conversion Cycle (CCC)
128.43 119.17 147.39 151.98 151.12 156.71 173.15 180.78 184.00 194.16 206.55
Capital & Investment Metrics
- - - - - - - - - - -
Invested Capital
19,767 19,131 22,261 23,233 24,387 24,673 25,188 25,661 27,151 26,999 28,545
Invested Capital Turnover
0.75 0.76 0.71 0.67 0.62 0.61 0.57 0.54 0.51 0.51 0.49
Increase / (Decrease) in Invested Capital
-4,620 -5,542 -2,927 -2,428 -2,764 -2,326 -3,357 -4,175 -3,836 -5,103 -4,584
Enterprise Value (EV)
32,388 39,802 36,395 34,992 32,735 28,930 29,738 27,102 29,130 29,334 28,754
Market Capitalization
17,427 24,972 20,415 18,405 15,817 11,703 11,431 8,437 9,831 10,129 8,962
Book Value per Share
$5.52 $4.74 $5.35 $5.61 $6.48 $6.70 $6.18 $6.29 $7.08 $7.03 $7.90
Tangible Book Value per Share
($11.82) ($12.53) ($13.08) ($13.23) ($13.17) ($13.43) ($13.81) ($14.11) ($14.31) ($14.50) ($14.46)
Total Capital
22,920 23,503 25,363 25,204 27,187 27,959 27,486 28,386 29,303 29,810 30,785
Total Debt
16,651 17,783 18,980 18,641 19,644 19,833 19,974 20,678 20,691 21,212 21,266
Total Long-Term Debt
16,230 16,002 16,400 16,547 16,584 18,161 18,495 18,698 19,668 19,103 18,497
Net Debt
14,954 14,483 15,661 16,383 16,653 16,607 17,725 18,009 18,548 18,411 19,041
Capital Expenditures (CapEx)
127 129 148 97 124 119 149 119 139 142 122
Debt-free, Cash-free Net Working Capital (DFCFNWC)
-905 -1,763 -2,222 -1,569 -1,426 -1,316 -739 -444 -30 -110 463
Debt-free Net Working Capital (DFNWC)
792 1,537 1,097 689 1,565 1,910 1,510 2,225 2,113 2,691 2,688
Net Working Capital (NWC)
371 -244 -1,483 -1,405 -1,495 238 31 245 1,090 582 -81
Net Nonoperating Expense (NNE)
168 256 354 871 266 228 332 448 244 678 91
Net Nonoperating Obligations (NNO)
13,498 13,411 15,878 16,670 16,844 16,547 17,676 17,953 18,539 18,401 19,026
Total Depreciation and Amortization (D&A)
244 269 259 259 272 266 283 300 304 306 321
Debt-free, Cash-free Net Working Capital to Revenue
-5.45% -10.66% -13.25% -9.63% -8.91% -8.30% -4.84% -2.96% -0.20% -0.74% 3.06%
Debt-free Net Working Capital to Revenue
4.77% 9.29% 6.54% 4.23% 9.78% 12.05% 9.89% 14.82% 14.16% 18.03% 17.75%
Net Working Capital to Revenue
2.23% -1.47% -8.84% -8.62% -9.34% 1.50% 0.20% 1.63% 7.30% 3.90% -0.54%
Earnings Adjustments
- - - - - - - - - - -
Adjusted Basic Earnings per Share
$0.19 ($0.19) ($0.39) ($0.75) ($0.12) $0.42 $0.07 ($0.77) ($0.18) ($1.18) $0.05
Adjusted Weighted Average Basic Shares Outstanding
1.14B 1.13B 1.13B 1.13B 1.12B 1.12B 1.12B 1.12B 1.12B 1.11B 1.11B
Adjusted Diluted Earnings per Share
$0.18 ($0.19) ($0.39) ($0.75) ($0.12) $0.42 $0.07 ($0.77) ($0.18) ($1.18) $0.05
Adjusted Weighted Average Diluted Shares Outstanding
1.16B 1.13B 1.13B 1.13B 1.12B 1.12B 1.14B 1.12B 1.12B 1.11B 1.12B
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
1.15B 1.13B 1.13B 1.13B 1.13B 1.12B 1.12B 1.12B 1.12B 1.11B 1.11B
Normalized Net Operating Profit after Tax (NOPAT)
527 639 703 573 449 731 534 475 356 519 472
Normalized NOPAT Margin
13.54% 15.11% 16.22% 13.77% 11.75% 16.41% 13.87% 12.26% 9.71% 13.36% 13.12%
Pre Tax Income Margin
7.56% -5.84% -7.48% -5.91% -12.23% 11.35% 1.69% -23.80% -7.43% -30.85% 4.62%
Debt Service Ratios
- - - - - - - - - - -
EBIT to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios
- - - - - - - - - - -
Dividend Payout Ratio
-25.76% -3.98% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio
-25.76% -3.98% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Frequently Asked Questions About Teva Pharmaceutical Industries' Financials

When does Teva Pharmaceutical Industries's fiscal year end?

According to the most recent income statement we have on file, Teva Pharmaceutical Industries' financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has Teva Pharmaceutical Industries' net income changed over the last 9 years?

Teva Pharmaceutical Industries' net income appears to be on a downward trend, with a most recent value of -$1.96 billion in 2024, falling from $1.60 billion in 2015. The previous period was -$615 million in 2023. View Teva Pharmaceutical Industries' forecast to see where analysts expect Teva Pharmaceutical Industries to go next.

What is Teva Pharmaceutical Industries's operating income?
Teva Pharmaceutical Industries's total operating income in 2024 was -$303 million, based on the following breakdown:
  • Total Gross Profit: $8.06 billion
  • Total Operating Expenses: $8.37 billion
How has Teva Pharmaceutical Industries revenue changed over the last 9 years?

Over the last 9 years, Teva Pharmaceutical Industries' total revenue changed from $19.65 billion in 2015 to $16.54 billion in 2024, a change of -15.8%.

How much debt does Teva Pharmaceutical Industries have?

Teva Pharmaceutical Industries' total liabilities were at $33.61 billion at the end of 2024, a 4.9% decrease from 2023, and a 38.3% increase since 2015.

How much cash does Teva Pharmaceutical Industries have?

In the past 9 years, Teva Pharmaceutical Industries' cash and equivalents has ranged from $963 million in 2017 to $6.95 billion in 2015, and is currently $3.30 billion as of their latest financial filing in 2024.

How has Teva Pharmaceutical Industries' book value per share changed over the last 9 years?

Over the last 9 years, Teva Pharmaceutical Industries' book value per share changed from 27.68 in 2015 to 4.74 in 2024, a change of -82.9%.



This page (NYSE:TEVA) was last updated on 5/28/2025 by MarketBeat.com Staff
From Our Partners